SEARCH

SEARCH BY CITATION

References

  • 1
    Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 16778.
  • 2
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 3
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 4
    Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19: 2537.
  • 5
    Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 26383.
  • 6
    Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49 (Suppl.): S11221.
  • 7
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 8
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 9
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 10
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998; 339: 618.
  • 11
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 125663.
  • 12
    Chang TT, Gish RG, de MAN R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 13
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 257688.
  • 14
    Lai CL, ShouvaL D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 15
    Vinayek R, Shakil O. Adverse events associated with interferon-alfa therapy in patients with chronic viral hepatitis. Viral Hep Rev 1997; 3: 16777.
  • 16
    Van ZM, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 116371.
  • 17
    Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 18
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 19
    Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S18595.
  • 20
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 21
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 22
    Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 48695.
  • 23
    Heathcote EJ, Gane EJ, de Man RA, et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2009; 50 (Suppl.): 533A.
  • 24
    Marcellin P, Buti M, Krastev Z, et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102); preliminary analysis. Hepatology 2009; 50 (Suppl.): 532A.
  • 25
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 26
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 21926.
  • 27
    Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opin Emerg Drugs 2004; 9: 20721.
  • 28
    Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 115.
  • 29
    Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44: 593606.
  • 30
    Liaw Y-F, Leung NWY, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 31
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 1219.
  • 32
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 33
    Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 78591.
  • 34
    Manolakopoulos S, Bethanis S, Elefsiniotis J, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006; 23: 78795.
  • 35
    Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 16270.
  • 36
    Di Bisceglie A, Lai C-L, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44 (Suppl. 1): 230A.
  • 37
    Tenney D, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S77.
  • 38
    Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 143744.
  • 39
    Chang TT, Chao Y-C, Kayamakoglou S, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral naive HBeAg(+) patients (ETV022/901). Hepatology 2006; 44 (Suppl. 1): 229A.
  • 40
    Poordad F, Dieterich DT, Min AD, et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). Gastroenterology 2006; 130 (Suppl. 1): A-848.
  • 41
    Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 148895.
  • 42
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 30713.
  • 43
    Lampertico P, Vigano P, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 14149.
  • 44
    Manolakopoulos S, Bethanis S, Koutsounas S, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008; 27: 26673.
  • 45
    van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 31825.
  • 46
    van Bommel F, De Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 7380.
  • 47
    Berg T, Moller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). J Hepatol 2008; 48 (Suppl. 2): S34.
  • 48
    Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44: 42231.
  • 49
    Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol 2008; 3: 52538.
  • 50
    Kumar A. Tenofovir disoproxil fumarate. Drugs 2003; 63: 160910.
  • 51
    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14227.
  • 52
    Manesis EK, Hadziyannis SJ. Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 1019.
  • 53
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 30613.
  • 54
    Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 108492.
  • 55
    Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 45967.
  • 56
    Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 216979.
  • 57
    Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 58
    Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 42834.
  • 59
    Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 11517.
  • 60
    Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 114150.
  • 61
    Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010; 82: 113542.
  • 62
    Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 127682.
  • 63
    Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 7508.
  • 64
    Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB). Hepatology 2009; 50 (Suppl.): 533A.
  • 65
    Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 66
    Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 74855.
  • 67
    Yoon SK, Jang JW, Kim CW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005; 48: 3419.
  • 68
    Wu IC, Shiffman ML, Tong MJ, et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis 2008; 47: 130511.
  • 69
    Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 4918.
  • 70
    Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontiuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 (Suppl. 1): 231A.
  • 71
    Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 40515.
  • 72
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 152131.
  • 73
    Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 34856.